The FDA’s Oncologic Drugs Advisory Committee tomorrow will review US WorldMeds’ potential high-risk pediatric neuroblastoma drug to reduce the risk of relapse after front-line therapy. USWM is seeking an approval via an externally controlled trial, a move not normally enough for a full approval, but which the FDA says it…
Click here to view original post
